Assessment of Disease Severity and Quality of Life in Patients with Atopic Dermatitis from South Korea
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Data illustrating the impact of atopic dermatitis (AD) on lives of adults withAD in South Korea are limited. Objective: To assess the AD disease severity and its impact on quality of life (QoL) in patientswith AD from South Korea. Methods: Patients with AD utilizing the specialist dermatology services of major hospitals inSouth Korea were assessed for disease severity using Eczema Area and Severity Index (EASI)score, for QoL using Dermatology Life Quality Index (DLQI) (for QoL), and for comorbiditiesand treatment experience via retrospective review of 12-month medical records. Clinical andsociodemographic characteristics were also measured. Results: Of the 1,163 patients, 695 (59.8%) were men (mean age [years]±standard devia-tion: 31.6±12.1). Overall, 52.9% (n=615) patients had moderate-to-severe disease (EASI>7). The QoL of 72.3% (n=840) patients was affected moderately-to-severely (DLQI score: 6~30). Systemic immunosuppressants were used ≥1 over past 12 months in 51.9% (n=603) patients,and the most commonly used were cyclosporines (45.7%, n=531) and systemic corticosteroids(40.5%, n=471). Approximately, 10.8% (n=126) patients consulted or received treatment forAD-related eye problem. Of these, 40% (n=50) patients reported poor, very poor, or complete-ly blind status; approximately, 16.7% patients (n=192) reported having depression or anxiety;and 35.5% (n=410) reported suicidal ideation or suicidal attempt. Conclusion: A large proportion of patients had moderate-to-severe AD, a compromisedQoL, and ocular or mental health comorbidities, indicating a high disease burden despite sys-temic treatment. These findings highlight the importance of a holistic approach for the evalu-ation and treatment of patients with AD.
Abstract
Background: Data illustrating the impact of atopic dermatitis (AD) on lives of adults withAD in South Korea are limited. Objective: To assess the AD disease severity and its impact on quality of life (QoL) in patientswith AD from South Korea. Methods: Patients with AD utilizing the specialist dermatology services of major hospitals inSouth Korea were assessed for disease severity using Eczema Area and Severity Index (EASI)score, for QoL using Dermatology Life Quality Index (DLQI) (for QoL), and for comorbiditiesand treatment experience via retrospective review of 12-month medical records. Clinical andsociodemographic characteristics were also measured. Results: Of the 1,163 patients, 695 (59.8%) were men (mean age [years]±standard devia-tion: 31.6±12.1). Overall, 52.9% (n=615) patients had moderate-to-severe disease (EASI>7). The QoL of 72.3% (n=840) patients was affected moderately-to-severely (DLQI score: 6~30). Systemic immunosuppressants were used ≥1 over past 12 months in 51.9% (n=603) patients,and the most commonly used were cyclosporines (45.7%, n=531) and systemic corticosteroids(40.5%, n=471). Approximately, 10.8% (n=126) patients consulted or received treatment forAD-related eye problem. Of these, 40% (n=50) patients reported poor, very poor, or complete-ly blind status; approximately, 16.7% patients (n=192) reported having depression or anxiety;and 35.5% (n=410) reported suicidal ideation or suicidal attempt. Conclusion: A large proportion of patients had moderate-to-severe AD, a compromisedQoL, and ocular or mental health comorbidities, indicating a high disease burden despite sys-temic treatment. These findings highlight the importance of a holistic approach for the evalu-ation and treatment of patients with AD.
참고문헌 (26)
- Langan SM, "Atopic dermatitis", Lancet, 396, pp.758~ (2020)
- Margolis JS, "Persistence of mild to moderate atopic dermatitis", JAMA Dermatol, 150, pp.593~600 (2014)
- "Korea National Health and Nutrition Examination Survey (KNHANES 2009-2019). Chronic disease prevalence: health survey in Korean adults" (2022)[URL]
- 김민주, "Prevalence of Atopic Dermatitis among Korean Adults Visiting Health Service Center of the Catholic Medical Center in Seoul Metropolitan Area, Korea", Journal of Korean Medical Science, 25(12), pp.1828~1830 (2010), 대한의학회
- Oninla OA, "Atopic dermatitis - essential issues" (2021), IntechOpen
- Schmitt J, "Harmonising Outcome Measures for Atopic Dermatitis (HOME) Initiative. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation", J Allergy Clin Immunol, 132, pp.1337~1347 (2013)
- Howard Chu, "Clinical Diversity of Atopic Dermatitis: A Review of 5,000 Patients at a Single Institute", Allergy, Asthma & Immunology Research, 9(2), pp.158~168 (2017), 대한천식알레르기학회
- Mann C, "Sleep disturbance in patients with urticaria and atopic dermatitis : an underestimated burden", Acta Derm Venereol, 100, pp.adv00073~ (2020)
- Holm EA, "Life quality assessment among patients with atopic eczema", Br J Dermatol, 154, pp.719~725 (2006)
- Kwak Y, "Health-related quality of life and mental health of adults with atopic dermatitis", Arch Psychiatr Nurs, 31, pp.516~521 (2017)
- Gochnauer H, "The psychosocial impact of atopic dermatitis", Adv Exp Med Biol, 1027, pp.57~69 (2017)
- Koszorú K, "Quality of life in patients with atopic dermatitis", Cutis, 104, pp.174~177 (2019)
- 김정은, "2019 Consensus Korean Diagnostic Guidelines to Define Severity Classification and Treatment Refractoriness for Atopic Dermatitis: Objective and Subjective Assessment of Severity", Annals of Dermatology, 31(6), pp.654~661 (2019), 대한피부과학회[DOI]
- Eichenfield LF, "Current guidelines for the evaluation and management of atopic dermatitis : a comparison of the Joint Task Force practice parameter and American Academy of Dermatology guidelines", J Allergy Clin Immunol, 139(4S), pp.S49~S57 (2017)
- 염혜영, "Current Management of Moderate-to-Severe Atopic Dermatitis: A Survey of Allergists, Pediatric Allergists and Dermatologists in Korea", Allergy, Asthma & Immunology Research, 10(3), pp.253~259 (2018), 대한천식알레르기학회
- Wei W, "A real-world study evaluating adeQUacy of Existing Systemic Treatments for patients with moderate-to-severe Atopic Dermatitis(QUEST-AD) : baseline treatment patterns and unmet needs assessment", Ann Allergy Asthma Immunol, 123, pp.381~388 (2019)
- Leshem YA, "What the eczema area and severity index score tells us about the severity of atopic dermatitis : an interpretability study", Br J Dermatol, 172, pp.1353~1357 (2015)
- Hongbo Y, "Translating the science of quality of life into practice : what do dermatology life quality index scores mean?", J Invest Dermatol, 125, pp.659~664 (2005)
- Rehal B, "Health outcome measures in atopic dermatitis:a systematic review of trends in disease severity and qualityof-life instruments 1985-2010", LoS One, 6, pp.10~ (2011)[DOI]
- Revicki DA, "Relationship between clinical response to therapy and healthrelated quality of life outcomes in patients with moderate to severe plaque psoriasis", Dermatology, 216, pp.260~270 (2008)
- Boguniewicz M, "Expert perspectives on management of moderate-tosevere atopic dermatitis : a multidisciplinary consensus addressing current and emerging therapies", J Allergy Clin Immunol Pract, 5, pp.1519~1531 (2017)
- Calzavara Pinton P, "Diagnosis and management of moderate to severe adult atopic dermatitis : a Consensus by the Italian Society of Dermatology and Venereology(SIDeMaST), the Italian Association of Hospital Dermatologists(ADOI), the Italian Society of Allergy, Asthma and Clinical Immunology(SIAAIC), and the Italian Society of Allergological, Environmental and Occupational Dermatology(SIDAPA)", G Ital Dermatol Venereol, 153, pp.133~145 (2018)
- Vakharia PP, "Severity strata for five patient-reported outcomes in adults with atopic dermatitis", Br J Dermatol, 178, pp.925~930 (2018)
- 김동하, "Quality of Life and Disease Severity Are Correlated in Patients with Atopic Dermatitis", Journal of Korean Medical Science, 27(11), pp.1327~1332 (2012), 대한의학회
- Sandhu JK, "Association between atopic dermatitis and suicidality : a systematic review and metaanalysis", JAMA Dermatol, 155, pp.178~187 (2019)
- Simpson EL, "Association of inadequately controlled disease and disease severity with patient-reported disease burden in adults with atopic dermatitis", JAMA Dermatol, 154, pp.903~912 (2018)